Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat COVID-19 in India

 Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat COVID-19 in India

Shots:

  • The CDSCO has granted a EUA for Roche’s casirivimab and imdevimab to treat COVID-19 in India. The approval of the Ab cocktail was based on the data that has been filed for the EUA in the US and the CHMP’s opinion in the EU
  • Roche will import the globally manufactured product batches to India and is collaborated with Cipla for pan-India distribution. At a global level, Roche and Regeneron are collaborating to jointly address the increasing demand
  • Earlier, Roche has reported the global P-III trial of Abs vs PBO in 4,567 high-risk non-hospitalized COVID-19 patients and showed a 70% reduction in the risk of hospitalization or death and also shortened the duration of symptoms @4days

Click here to­ read full press release/ article | Ref: Cipla | Image: Cipla

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post